

Pancreatic Safety of Incretin-Based Drugs â€™ FDA and

New England Journal of Medicine

370, 794-797

DOI: [10.1056/nejmp1314078](https://doi.org/10.1056/nejmp1314078)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 229.	2.4	6
3	Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2014, 14, 64-70.	0.7	12
4	GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?. <i>Drug Design, Development and Therapy</i> , 2014, 8, 677.	4.3	4
5	Systematic Approach to Pharmacovigilance beyond the Limits: The Southern Network on Adverse Reactions (SONAR) Projects. <i>Advances in Pharmacoepidemiology & Drug Safety</i> , 2014, 3, .	0.1	2
6	Adverse Effects of GLP-1 Receptor Agonists. <i>Review of Diabetic Studies</i> , 2014, 11, 202-230.	1.3	227
7	New analyses of pancreatitis risk with incretin-based therapies. <i>Pharmacy Today</i> , 2014, 20, 17.	0.0	0
8	Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. <i>Clinical Investigation</i> , 2014, 4, 729-743.	0.0	3
9	Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1277-1289.	1.9	6
10	Cardiovascular impact of drugs used in the treatment of diabetes. <i>Therapeutic Advances in Chronic Disease</i> , 2014, 5, 245-268.	2.5	54
11	Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1346-1353.	2.6	39
12	Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2014, 5, 95-123.	3.2	13
13	Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries. <i>Diabetes Therapy</i> , 2014, 5, 499-520.	2.5	36
14	Incretin-mimetic therapies and pancreatic disease: a review of observational data. <i>Current Medical Research and Opinion</i> , 2014, 30, 2471-2481.	1.9	16
15	Diabetes therapy and cancer risk: Where do we stand when treating patients?. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 620-628.	1.3	1
16	Incretin-based therapy and pancreatic beta cells. <i>Diabetes and Metabolism</i> , 2014, 40, 411-422.	2.9	9
17	Commentary: metformin use is associated with reduced gastric cancer risk. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1239-1239.	3.7	2
18	Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2763-2773.	8.6	211
19	Pancreatic Safety of Newer Incretin-Based Therapies: Are the "-tides" Finally Turning?. <i>Diabetes</i> , 2014, 63, 2219-2221.	0.6	8

#	ARTICLE	IF	CITATIONS
20	Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes. Postgraduate Medicine, 2014, 126, 66-84.	2.0	10
21	Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2014, 9, 659-670.	2.4	14
22	Incretin-based therapies in prediabetes: Current evidence and future perspectives. World Journal of Diabetes, 2014, 5, 817.	3.5	26
23	Typ-2-Diabetes. , 2014, , 107-202.		0
24	Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus. Drugs, 2014, 74, 2161-2174.	10.9	42
25	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opinion on Drug Discovery, 2014, 9, 1223-1251.	5.0	23
26	Sitagliptin-induced pancreatitis "a longer road than expected. Clinical Case Reports (discontinued), 2014, 2, 149-152.	0.5	9
27	Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects. Drug Safety, 2014, 37, 1003-1010.	3.2	10
28	Commentary: metformin use is associated with reduced gastric cancer risk " authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 1239-1240.	3.7	1
29	Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes, Obesity and Metabolism, 2014, 16, 1247-1256.	4.4	60
30	Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs, 2014, 74, 1927-1946.	10.9	24
31	Cystic fibrosis related diabetes "a new perspective on the optimal management of postprandial glycemia. Journal of Diabetes and Its Complications, 2014, 28, 904-911.	2.3	22
32	Cancers du pancr�as et s�curit� des incr�tines : �tat des lieux en 2014. Medecine Des Maladies Metaboliques, 2014, 8, 380-391.	0.1	0
33	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. Diabetes Care, 2014, 37, 2647-2659.	8.6	58
34	Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors. Endocrine Reviews, 2014, 35, 992-1019.	20.1	439
35	Can Bayliss and Starling gut hormones cure a worldwide pandemic?. Journal of Physiology, 2014, 592, 5153-5167.	2.9	8
36	Therapies for inter-relating diabetes and obesity " GLP-1 and obesity. Expert Opinion on Pharmacotherapy, 2014, 15, 2487-2500.	1.8	37
38	Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?. Expert Opinion on Drug Safety, 2014, 13, 1469-1481.	2.4	15

#	ARTICLE	IF	CITATIONS
39	Risk of pancreatitis in patients treated with incretin-based therapies. <i>Diabetologia</i> , 2014, 57, 1320-1324.	6.3	84
40	FDA and EMA assess the pancreatic safety of incretin-based drugs. <i>Reactions Weekly</i> , 2014, 1492, 1-1.	0.0	0
41	Treatment of Type 2 Diabetes Mellitus in the Older Adult: A Review. <i>Endocrine Practice</i> , 2014, 20, 722-736.	2.1	7
43	The safety of incretin based drugs. <i>BMJ, The</i> , 2014, 348, g2779-g2779.	6.0	4
44	CVD and type 2 diabetes: The nurse prescriber's role. <i>British Journal of Cardiac Nursing</i> , 2014, 9, 325-329.	0.1	0
45	Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. <i>Endocrine Journal</i> , 2014, 61, 949-959.	1.6	38
47	Incretin physiology and pathophysiology from an Asian perspective. <i>Journal of Diabetes Investigation</i> , 2015, 6, 495-507.	2.4	62
48	Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option. <i>International Journal of Clinical Practice</i> , 2015, 69, 1427-1437.	1.7	14
49	Type 2 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15019.	30.5	1,308
50	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan " 2015. <i>Endocrine Practice</i> , 2015, 21, 1-87.	2.1	443
51	Cardiovascular outcome trials of glucose-lowering drugs in type 2 diabetes: 10 frequently asked questions. <i>Practical Diabetes</i> , 2015, 32, 301-304.	0.3	0
52	The role of GLP-1 receptor agonists as weight loss agents in patients with and without type 2 diabetes. <i>Practical Diabetes</i> , 2015, 32, 297.	0.3	16
53	10.2 Diabetes mellitus. , 2015, , .		0
54	Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 241.	2.4	28
55	Use of Dipeptidyl Peptidase-4 Inhibitors in a Subset of Patients with Cystic Fibrosis Related Diabetes. <i>Journal of Diabetes & Metabolism</i> , 2015, 06, .	0.2	0
56	Pulmonary Artery Relaxation was Best with Increasing GLP1 than the Metabolic Improvement in Patients with Type 2 Diabetes. <i>Journal of Diabetes & Metabolism</i> , 2015, s13, .	0.2	0
57	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. <i>Current Diabetes Reviews</i> , 2015, 11, 17-31.	1.3	44
58	Incretin System in the Pathogenesis of Type 2 Diabetes and the Role of Incretin Based Therapies in the Management of Type 2 Diabetes. , 2015, , .		1

#	ARTICLE	IF	CITATIONS
59	Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2015, 53, 19-22.	0.6	2
60	The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-28.	2.3	65
61	Cystic Fibrosis Related Diabetes. , 2015, , .		0
62	Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment. <i>Diabetes Care</i> , 2015, 38, 1161-1172.	8.6	170
63	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 232-242.	27.0	2,188
64	Regional Variation in Use of a New Class of Antidiabetic Medication Among Medicare Beneficiaries. <i>Annals of Pharmacotherapy</i> , 2015, 49, 285-292.	1.9	7
65	Liraglutide: A Review of Its Use in the Management of Obesity. <i>Drugs</i> , 2015, 75, 899-910.	10.9	28
66	Smoke or Fire? Acute Pancreatitis and the Liraglutide Trials. <i>Diabetes Care</i> , 2015, 38, 948-950.	8.6	7
67	Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015, 6, 109-134.	3.2	40
68	Optical Control of Insulin Secretion Using an Incretin Switch. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 15565-15569.	13.8	80
69	<scp>GLP</scp> receptor agonists: Nonglycemic clinical effects in weight loss and beyond. <i>Obesity</i> , 2015, 23, 1119-1129.	3.0	74
70	Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. <i>Advances in Therapy</i> , 2015, 32, 1065-1084.	2.9	8
71	An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks. <i>Toxicologic Pathology</i> , 2015, 43, 1093-1102.	1.8	10
72	Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, e13-e17.	2.8	28
73	Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice—EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study. <i>Advances in Therapy</i> , 2015, 32, 838-853.	2.9	32
74	Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 291-300.	2.8	25
75	A review of gliptins for 2014. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 43-62.	1.8	88
76	Demographics, Epidemiology, and Inheritance of Pancreatic Ductal Adenocarcinoma. <i>Seminars in Oncology</i> , 2015, 42, 8-18.	2.2	112

#	ARTICLE	IF	CITATIONS
77	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.	6.3	598
78	Pharmacologic Treatment of Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2015, 49, 540-556.	1.9	69
79	National trends in incidence and outcomes of acute pancreatitis among type 2 diabetics and non-diabetics in Spain (2001â€“2011). <i>Pancreatology</i> , 2015, 15, 64-70.	1.1	36
80	Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture. <i>Diabetes</i> , 2015, 64, 317-326.	0.6	65
81	Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 505-524.	2.4	92
82	Potential side effects to GLP-1 agonists: understanding their safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 207-218.	2.4	41
83	Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials. <i>Diabetes Care</i> , 2015, 38, 1058-1066.	8.6	40
84	Sitagliptin for Type 2 diabetes: a 2015 update. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 597-610.	1.5	20
85	ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2015, 9, 139-142.	3.6	21
86	Liraglutide for Type 2 diabetes and obesity: a 2015 update. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 753-767.	1.5	62
87	Drug Repositioning for Diabetes Based on 'Omics' Data Mining. <i>PLoS ONE</i> , 2015, 10, e0126082.	2.5	74
88	Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes â€“ focus on pancreatitis and pancreas cancer. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 171-180.	2.4	24
89	Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. <i>Drugs</i> , 2015, 75, 1071-1094.	10.9	200
91	Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 567-575.	1.9	14
92	The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. <i>Drugs</i> , 2015, 75, 935-945.	10.9	46
93	Authorâ€™s Reply to De Ponti et al.: â€œPharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitusâ€• <i>Clinical Pharmacokinetics</i> , 2015, 54, 449-451.	3.5	0
94	Pharmacologic Treatment of Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2015, 49, 700-714.	1.9	23
95	Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2015, 49, 688-699.	1.9	7

#	ARTICLE	IF	CITATIONS
96	Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2015, 75, 651-663.	10.9	29
97	Cardiometabolic Effects of a New Class of Antidiabetic Agents. <i>Clinical Therapeutics</i> , 2015, 37, 1178-1194.	2.5	39
98	Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1005-1020.	3.3	8
99	An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. <i>Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews</i> , 2015, 33, 67-124.	2.9	43
100	Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2015, 75, 777-796.	10.9	24
101	Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 243-249.	2.8	9
103	Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys. <i>Toxicologic Pathology</i> , 2015, 43, 1004-1014.	1.8	4
104	User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. <i>Postgraduate Medicine</i> , 2015, 127, 818-826.	2.0	45
105	Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. <i>Clinical Drug Investigation</i> , 2015, 35, 675-684.	2.2	14
106	Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points. <i>Current Medical Research and Opinion</i> , 2015, 31, 1267-1270.	1.9	13
107	Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. <i>Postgraduate Medicine</i> , 2015, 127, 480-493.	2.0	9
108	GLP-1 Receptor Agonists. <i>The Diabetes Educator</i> , 2015, 41, 32S-46S.	2.5	11
109	Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 687.	7.4	707
110	Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice. <i>Diabetologia</i> , 2015, 58, 2582-2591.	6.3	26
111	GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. <i>Acta Diabetologica</i> , 2015, 52, 1129-1133.	2.5	15
112	Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1052.	7.4	305
113	Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. <i>BMJ Open</i> , 2015, 5, e009579.	1.9	30
114	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). <i>BMJ, The</i> , 2015, 351, h5364.	6.0	53

#	ARTICLE	IF	CITATIONS
115	Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. <i>Diabetes Care</i> 2015;38:1089-1098. <i>Diabetes Care</i> , 2015, 38, e106-e107.	8.6	1
116	Pancreatitis in incretin-based therapies. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e37-e38.	1.5	1
117	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015, 38, 140-149.	8.6	2,326
118	Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 430-434.	4.4	22
119	DPP-4 inhibitors: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 127-140.	2.4	55
120	Chronic Continuous Exenatide Infusion Does Not Cause Pancreatic Inflammation and Ductal Hyperplasia in Non-Human Primates. <i>American Journal of Pathology</i> , 2015, 185, 139-150.	3.8	16
121	Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 149-159.	2.4	8
122	Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,515 patients from observational studies. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 32-41.	4.4	54
123	Glucagon-Like Peptide-1 Receptor Agonists Increase Pancreatic Mass by Induction of Protein Synthesis. <i>Diabetes</i> , 2015, 64, 1046-1056.	0.6	42
124	GLP-1 Agonist Use in a Patient With an Explainable Cause of Pancreatitis. <i>AACE Clinical Case Reports</i> , 2016, 2, e82-e85.	1.1	1
125	An Update on the Effect of Incretin-Based Therapies on β -Cell Function and Mass. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 99.	4.7	45
126	Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy. <i>Current Diabetes Reviews</i> , 2016, 12, 403-413.	1.3	35
127	Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017004.	1.3	5
128	The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer. <i>Gut and Liver</i> , 2016, 10, 665-671.	2.9	19
129	Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. <i>Frontiers in Immunology</i> , 2016, 7, 154.	4.8	95
130	Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients. <i>Medicine (United States)</i> , 2016, 95, e2603.	1.0	15
131	Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus. <i>Pancreas</i> , 2016, 45, 228-233.	1.1	2
132	Early pancreatic carcinogenesis - risk factors, early symptoms, and the impact of antidiabetic drugs. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, e19-e25.	1.6	7

#	ARTICLE	IF	CITATIONS
133	Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 333-347.	4.4	161
134	Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 558-570.	4.4	134
139	Diabetes mellitus in the older adult. , 2016, , 421-435.		0
140	Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes. <i>Cell Reports</i> , 2016, 17, 2845-2856.	6.4	22
141	Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. <i>Current Diabetes Reports</i> , 2016, 16, 44.	4.2	19
142	Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors. <i>Journal of Food and Drug Analysis</i> , 2016, 24, 450-454.	1.9	3
143	Incretin-based therapy: Is the risk of pancreatitis driven by cardiovascular disease?. <i>Diabetes Research and Clinical Practice</i> , 2016, 117, 28-31.	2.8	2
144	NUEVOS FÁRMACOS EN DIABETES MELLITUS. <i>Revista Médica Clínica Las Condes</i> , 2016, 27, 235-256.	0.2	4
146	DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty. <i>Diabetes Care</i> , 2016, 39, 735-737.	8.6	19
147	GLP-1 as a target for therapeutic intervention. <i>Current Opinion in Pharmacology</i> , 2016, 31, 44-49.	3.5	32
148	Albiglutide: a unique GLP-1 receptor agonist. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1557-1569.	3.1	16
149	Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials. <i>Diabetes Therapy</i> , 2016, 7, 725-742.	2.5	17
150	Modifiable and non-modifiable risk factors for pancreatic cancer: A review. <i>Cancer Letters</i> , 2016, 381, 269-277.	7.2	184
151	Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. <i>Clinical and Experimental Immunology</i> , 2016, 185, 1-21.	2.6	332
152	Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 317-332.	4.4	211
153	Effect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus. <i>Journal of Veterinary Internal Medicine</i> , 2016, 30, 92-100.	1.6	19
154	Never Waste a Good Crisis: Confronting Reproducibility in Translational Research. <i>Cell Metabolism</i> , 2016, 24, 348-360.	16.2	105
155	Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. <i>Diabetes Care</i> , 2016, 39, S154-S164.	8.6	36

#	ARTICLE	IF	CITATIONS
156	Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, S137-S145.	8.6	77
158	Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 671-673.	4.4	1
160	Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. <i>Diabetes Therapy</i> , 2016, 7, 621-639.	2.5	21
161	Glucagon-like peptide-1 receptor agonists and risk of breast cancer. <i>BMJ</i> , The, 2016, 355, i5519.	6.0	2
162	Regulation of food intake and the development of anti-obesity drugs. <i>Drug Discoveries and Therapeutics</i> , 2016, 10, 62-73.	1.5	12
164	Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4-inhibitors and GLP-1-agonists. <i>BMC Family Practice</i> , 2016, 17, 146.	2.9	3
165	Incretin-based therapies linked to pancreatic cancer?. <i>Reactions Weekly</i> , 2016, 1626, 5-5.	0.0	0
166	Hyperglycemia Management In Patients With Posttransplantation Diabetes. <i>Endocrine Practice</i> , 2016, 22, 454-465.	2.1	17
167	Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 281-288.	4.4	6
169	Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 7-19.	2.4	23
170	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2016, 12, 566-592.	9.6	292
171	Dipeptidyl peptidase-4 inhibitors. , 2016, , 45-60.		0
172	Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 357-371.	4.7	12
173	Pancreatitis, pancreatic cancer, and diabetes. <i>Practical Diabetes</i> , 2016, 33, 77-78.	0.3	5
174	Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation. <i>Neuropeptides</i> , 2016, 57, 21-34.	2.2	35
175	Incretin-Based Therapy for Diabetes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1488-1496.	2.8	32
176	DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 273-284.	2.6	19
177	Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 203-216.	4.4	322

#	ARTICLE	IF	CITATIONS
178	A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2016, 11, 217-232.	2.4	4
179	Type 2 Diabetes Medication Review. American Journal of the Medical Sciences, 2016, 351, 342-355.	1.1	24
180	The safety of incretin based drug treatments for type 2 diabetes. BMJ, The, 2016, 352, i801.	6.0	4
181	Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Review of Clinical Pharmacology, 2016, 9, 385-399.	3.1	20
182	Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ, The, 2016, 352, i581.	6.0	78
184	GLP-1 based therapies: clinical implications for gastroenterologists. Gut, 2016, 65, 702-711.	12.1	34
185	Novel Therapeutic Approaches in Diabetes. Endocrine Development, 2016, 31, 43-56.	1.3	15
186	Liraglutide for treating type 1 diabetes. Expert Opinion on Biological Therapy, 2016, 16, 579-590.	3.1	15
187	Diabetes and Cancer. Endocrine Development, 2016, 31, 135-145.	1.3	12
188	Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opinion on Drug Safety, 2016, 15, 697-707.	2.4	7
189	Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know. Pancreatology, 2016, 16, 10-13.	1.1	31
190	Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety, 2016, 15, 249-264.	2.4	6
191	Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Review of Clinical Pharmacology, 2016, 9, 241-265.	3.1	25
192	An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs, 2016, 25, 145-158.	4.1	41
193	The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy. International Journal of Cardiology, 2016, 202, 731-735.	1.7	19
194	Clinical use of GLP-1 agonists and DPP4 inhibitors. Pancreatology, 2016, 16, 8-9.	1.1	7
196	Management of Type 2 Diabetes Mellitus. , 2016, , 839-853.e2.		6
197	Acute plasma amylase increase after glucagon-like peptide 1 receptor agonist exenatide administration in Type 2 diabetes. Diabetic Medicine, 2017, 34, 591-592.	2.3	5

#	ARTICLE	IF	CITATIONS
198	Cardiovascular safety and benefits of GLP-1 receptor agonists. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 351-363.	2.4	30
199	Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 261-265.	1.5	33
200	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 387-396.	2.4	16
201	Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 906-908.	4.4	90
202	Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options. <i>Diabetes and Metabolism</i> , 2017, 43, 110-124.	2.9	9
203	Sitagliptin: A Review in Type 2 Diabetes. <i>Drugs</i> , 2017, 77, 209-224.	10.9	83
204	Exenatide: pharmacokinetics, clinical use, and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 555-571.	1.8	58
205	Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. <i>Diabetes Research and Clinical Practice</i> , 2017, 126, 230-239.	2.8	22
206	The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. <i>Advances in Therapy</i> , 2017, 34, 638-657.	2.9	3
207	Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. <i>Diabetes Care</i> , 2017, 40, 647-654.	8.6	20
208	Acute Pancreatitis. <i>New England Journal of Medicine</i> , 2017, 376, 596-599.	27.0	52
209	Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. <i>Current Cardiology Reports</i> , 2017, 19, 25.	2.9	2
210	Dulaglutide for the treatment of type 2 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 485-496.	3.1	30
211	Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2017, 40, 966-972.	8.6	63
212	Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2017, 5, CD012204.	2.8	31
213	Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. <i>Diabetes Care</i> , 2017, 40, 839-848.	8.6	49
214	Cuparane sesquiterpenes from <i>Laurencia natalensis</i> Kylin as inhibitors of alpha-glucosidase, dipeptidyl peptidase IV and xanthine oxidase. <i>Algal Research</i> , 2017, 25, 178-183.	4.6	8
215	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. <i>American Journal of Medicine</i> , 2017, 130, S4-S17.	1.5	83

#	ARTICLE	IF	CITATIONS
216	Lixisenatide, a Onceâ€Daily Prandial Glucagonâ€Like Peptideâ€1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. <i>Pharmacotherapy</i> , 2017, 37, 927-943.	2.6	15
217	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. <i>American Journal of Cardiology</i> , 2017, 120, S4-S16.	1.6	60
218	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. <i>Current Diabetes Reports</i> , 2017, 17, 21.	4.2	33
219	The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMPâ€PKAâ€EGFRâ€STAT3 axis. <i>Oncogene</i> , 2017, 36, 4135-4149.	5.9	32
220	A highly specific ratiometric two-photon fluorescent probe to detect dipeptidyl peptidase IV in plasma and living systems. <i>Biosensors and Bioelectronics</i> , 2017, 90, 283-289.	10.1	52
221	Pasado, presente y futuro de la farmacoterapia para la obesidad. <i>ClÃnica E InvestigaciÃn En Arteriosclerosis</i> , 2017, 29, 256-264.	0.8	3
222	Current and emerging pharmacotherapies for obesity in Australia. <i>Obesity Research and Clinical Practice</i> , 2017, 11, 501-521.	1.8	9
223	Treatment of Diabetes and Obesity by Rationally Designed Peptide Agonists Functioning at Multiple Metabolic Receptors. <i>Endocrine Development</i> , 2017, 32, 165-182.	1.3	12
225	Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1133-1148.	2.4	3
226	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 1664-1675.	13.7	527
227	Past, present and future of pharmacotherapy for obesity. <i>ClÃnica E InvestigaciÃn En Arteriosclerosis (English Edition)</i> , 2017, 29, 256-264.	0.2	4
228	A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. <i>Advances in Therapy</i> , 2017, 34, 1791-1814.	2.9	21
229	The safety of albiglutide for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1089-1097.	2.4	4
231	Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 85-99.	27.6	163
232	Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. <i>Diabetes and Metabolism</i> , 2017, 43, 48-58.	2.9	83
233	Use of incretin agents and risk of acute and chronic pancreatitis: A populationâ€based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 401-411.	4.4	20
235	Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2017, 30, 202-210.	1.0	236
236	Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017, Volume 10, 79-87.	2.4	24

#	ARTICLE	IF	CITATIONS
237	Type II Diabetes, Peripheral Neuropathy, and Gout. , 2017, , 75-98.		1
238	Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing. BMC Geriatrics, 2017, 17, 226.	2.7	38
239	A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2017, 16, 112.	6.8	78
240	Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials. Endocrine Journal, 2017, 64, 191-206.	1.6	3
241	Clinical Safety and Tolerability of Vildagliptin â€“ Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. European Endocrinology, 2017, 13, 68.	1.5	23
242	The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety, 2018, 17, 387-405.	2.4	101
243	Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. Expert Review of Clinical Pharmacology, 2018, 11, 411-424.	3.1	12
244	Cognitive dysfunction and metabolic comorbidities in mood disorders: A repurposing opportunity for glucagon-like peptide 1 receptor agonists?. Neuropharmacology, 2018, 136, 335-342.	4.1	20
245	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. Cardiovascular Drugs and Therapy, 2018, 32, 213-222.	2.6	40
246	Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide. Drugs - Real World Outcomes, 2018, 5, 55-67.	1.6	2
247	Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 2018, 27, 740-756.	16.2	866
248	The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. Diabetes Care, 2018, 41, 1196-1203.	8.6	6
249	Treatment with GLP-1 Receptor Agonists. Endocrinology, 2018, , 1-45.	0.1	3
250	Newer GLP-1 receptor agonists and obesity-diabetes. Peptides, 2018, 100, 61-67.	2.4	54
251	A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 22-33.	4.4	183
252	What have we learnt from â€œreal worldâ€ data, observational studies and metaâ€ analyses. Diabetes, Obesity and Metabolism, 2018, 20, 47-58.	4.4	35
253	Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. Journal of Allergy and Clinical Immunology, 2018, 142, 1515-1528.e8.	2.9	63
254	Management of diabetes in older adults. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 206-218.	2.6	47

#	ARTICLE	IF	CITATIONS
255	Albiglutide for the management of type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2018, 13, 1-8.	2.4	11
256	Glucagon-like peptide 1 in health and disease. Nature Reviews Endocrinology, 2018, 14, 390-403.	9.6	304
257	Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews, 2018, 34, e3004.	4.0	49
258	Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review. Diabetes Therapy, 2018, 9, 877-890.	2.5	36
259	Treatment with Oral Drugs. Endocrinology, 2018, , 1-44.	0.1	0
260	Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis. Journal of Diabetes and Its Complications, 2018, 32, 113-122.	2.3	29
261	A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?. Indian Journal of Clinical Biochemistry, 2018, 33, 121-131.	1.9	14
262	Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies. Journal of Diabetes, 2018, 10, 94-111.	1.8	18
263	Pancreatic Cancer Epidemiology and Environmental Risk Factors. , 2018, , 1-22.		1
264	Pharmacotherapy of type 2 diabetes: An update. Metabolism: Clinical and Experimental, 2018, 78, 13-42.	3.4	144
265	Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors. Diabetes, Obesity and Metabolism, 2018, 20, 786-799.	4.4	18
266	Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 910-920.	4.4	20
267	Optimization of peptide-based polyagonists for treatment of diabetes and obesity. Bioorganic and Medicinal Chemistry, 2018, 26, 2873-2881.	3.0	18
268	Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes. Scientific Reports, 2018, 8, 15142.	3.3	17
270	Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy. Journal of Pancreatic Cancer, 2018, 4, 95-99.	0.9	13
271	Glucagon-Like Peptide 1 Receptor Agonists For Type 2 Diabetes: A Comprehensive Review of How to Weigh The Options, Select the Right Patients, and Maximize Benefits. Endocrine Practice, 2018, 24, 8-19.	2.1	1
272	Diabetes arising from pancreatic exocrine problems. Independent Nurse, 2018, 2018, 21-24.	0.1	0
274	Treatment with Oral Drugs. Endocrinology, 2018, , 527-569.	0.1	0

#	ARTICLE	IF	CITATIONS
275	Treatment with GLP-1 Receptor Agonists. <i>Endocrinology</i> , 2018, , 571-615.	0.1	1
276	iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2018, 31, 145-154.	1.0	22
277	Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 606-624.	17.8	69
278	Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence. <i>Pharmacotherapy</i> , 2018, 38, 739-757.	2.6	3
279	Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. <i>Advances in Therapy</i> , 2018, 35, 939-965.	2.9	14
280	Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review. <i>Journal of Transplantation</i> , 2018, 2018, 1-14.	0.5	19
281	The present and future treatment of pediatric type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 207-212.	2.4	1
282	Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. <i>Diabetes Care</i> , 2018, 41, 1998-2009.	8.6	32
283	Battle of GLP-1 delivery technologies. <i>Advanced Drug Delivery Reviews</i> , 2018, 130, 113-130.	13.7	84
284	SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. <i>Diabetes Care</i> , 2018, 41, 1543-1556.	8.6	137
285	The European Medicines Agency's approval of new medicines for type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2059-2063.	4.4	17
286	GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. <i>Endocrine Practice</i> , 2018, , .	2.1	1
287	The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications. <i>Diabetes</i> , 2018, 67, 1710-1719.	0.6	64
288	Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2018, 41, 1663-1671.	8.6	51
289	Clinical pharmacology of glucagon-like peptide-1 receptor agonists. <i>Hormones</i> , 2018, 17, 333-350.	1.9	43
290	The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2720.	2.6	84
291	Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-10.	2.3	21
292	Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features. <i>Clinical Drug Investigation</i> , 2019, 39, 805-819.	2.2	47

#	ARTICLE	IF	CITATIONS
293	Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson's Disease. <i>Neuroscience Bulletin</i> , 2019, 35, 1085-1096.	2.9	21
294	DPP-4 Inhibition and the Path to Clinical Proof. <i>Frontiers in Endocrinology</i> , 2019, 10, 376.	3.5	68
295	Management of Diabetes in Patients Undergoing Bariatric Surgery. <i>Current Diabetes Reports</i> , 2019, 19, 112.	4.2	17
296	Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. <i>Advances in Therapy</i> , 2019, 36, 3321-3339.	2.9	7
297	Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 468-484.	4.9	21
299	Incretin Physiology and Pharmacology in the Intensive Care Unit. <i>Critical Care Clinics</i> , 2019, 35, 341-355.	2.6	5
300	An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 691-701.	2.4	17
301	Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People. <i>Metabolic Syndrome and Related Disorders</i> , 2019, 17, 303-313.	1.3	4
302	Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials. <i>Diabetes Therapy</i> , 2019, 10, 1249-1270.	2.5	3
303	Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 377-387.	1.5	8
304	Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 80.	3.5	224
305	Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. <i>BMJ Open</i> , 2019, 9, e025806.	1.9	67
306	Case Reports of Pre-clinical Replication Studies in Metabolism and Diabetes. <i>Cell Metabolism</i> , 2019, 29, 795-802.	16.2	32
307	Pancreatic Safety in Studies of The Glucagon-Like Peptide-1 Receptor Agonist Albiglutide. <i>Endocrine Practice</i> , 2019, 25, 698-716.	2.1	0
308	Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1837-1848.	4.4	10
309	Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. <i>Drug Safety</i> , 2019, 42, 957-971.	3.2	22
310	Immunohistochemistry for Anti-diabetes Drug, Alogliptin Using a Newly Prepared Monoclonal Antibody: Its Precise Localization in Rat Small Intestine. <i>Acta Histochemica Et Cytochemica</i> , 2019, 52, 27-34.	1.6	6
311	The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 501-510.	1.8	13

#	ARTICLE	IF	CITATIONS
312	Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1498-1501.	4.4	61
313	Mushrooms of the Genus <i>Ganoderma</i> Used to Treat Diabetes and Insulin Resistance. <i>Molecules</i> , 2019, 24, 4075.	3.8	44
315	Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3070.	4.0	161
316	Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 2019, 56, 605-617.	2.5	50
317	Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1037-1042.	4.4	14
318	Drug-induced diabetes type 2: In silico study involving class B GPCRs. <i>PLoS ONE</i> , 2019, 14, e0208892.	2.5	20
319	Medications for the Treatment of Type II Diabetes. , 2019, , 101-106.		0
320	National Trends in Diabetes Medication Use in the United States: 2008 to 2015. <i>Journal of Pharmacy Practice</i> , 2020, 33, 433-442.	1.0	27
321	Incretins in obesity and diabetes. <i>Annals of the New York Academy of Sciences</i> , 2020, 1461, 104-126.	3.8	57
322	Cancer stem cells as therapeutic targets of pancreatic cancer. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 202-212.	1.9	17
323	Review: Diabetes, Obesity, and Cancer—Pathophysiology and Clinical Implications. <i>Endocrine Reviews</i> , 2020, 41, 33-52.	20.1	145
324	Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2101-2114.	1.8	3
325	Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection. <i>Current Obesity Reports</i> , 2020, 9, 391-401.	8.4	9
326	Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2020, 16, 642-653.	9.6	162
327	Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 68.	2.4	19
328	The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154295.	3.4	18
329	Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin. <i>Postgraduate Medicine</i> , 2020, 132, 667-675.	2.0	0
330	Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 461-468.	3.1	12

#	ARTICLE	IF	CITATIONS
331	Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2020, 13, 117955142090584.	1.9	17
332	New insights into potential nutritional effects of dietary saponins in protecting against the development of obesity. <i>Food Chemistry</i> , 2020, 318, 126474.	8.2	38
333	Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. <i>Current Medical Research and Opinion</i> , 2020, 36, 1117-1124.	1.9	3
334	GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. <i>Frontiers in Endocrinology</i> , 2020, 11, 178.	3.5	137
335	Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 912-921.	3.6	27
336	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: <i>Standards of Medical Care in Diabetes“2021</i>. <i>Diabetes Care</i> , 2021, 44, S40-S52.	8.6	179
337	Adverse Drug Effects Involving the Gastrointestinal System (Pharmacist Perspective). , 2021, , 297-339.		1
338	Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus. <i>Current Drug Safety</i> , 2021, 16, 32-51.	0.6	1
339	GLP-1 and Intestinal Diseases. <i>Biomedicines</i> , 2021, 9, 383.	3.2	20
340	Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes. <i>Annales D'Endocrinologie</i> , 2021, 82, 99-106.	1.4	3
341	Glucagon“like peptide“1 receptor agonist inhibits aeroallergen“induced activation of ILC2 and neutrophilic airway inflammation in obese mice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3433-3445.	5.7	32
342	CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology. <i>Cancers</i> , 2021, 13, 2191.	3.7	20
343	Dipeptidyl Peptidase 4 Inhibitor, an Update. <i>Journal of Korean Diabetes</i> , 2021, 22, 91-96.	0.3	0
344	Acute Pancreatitis-Induced Euglycemic Diabetic Ketoacidosis. <i>Cureus</i> , 2021, 13, e15949.	0.5	1
345	Safety of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021, 12, 645563.	3.5	66
346	Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors. <i>Diabetes Therapy</i> , 2021, 12, 2677-2690.	2.5	1
347	Glucose-Lowering Therapy in Patients With Postpancreatitis Diabetes Mellitus: A Nationwide Population-Based Cohort Study. <i>Diabetes Care</i> , 2021, 44, 2045-2052.	8.6	18
348	Diabetes and pancreatic cancer: Exploring the two-way traffic. <i>World Journal of Gastroenterology</i> , 2021, 27, 4939-4962.	3.3	28

#	ARTICLE	IF	CITATIONS
349	Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases. <i>Endocrine Research</i> , 2022, 47, 18-25.	1.2	19
350	The Effects of Major Mushroom Bioactive Compounds on Mechanisms That Control Blood Glucose Level. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 58.	3.5	17
352	Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). <i>Diabetes Care</i> , 2021, 44, 765-773.	8.6	91
353	<i>Antidiabetika.</i> , 2015, , 399-424.		1
354	<i>Antidiabetika.</i> , 2017, , 299-315.		1
355	<i>Antidiabetika.</i> , 2019, , 471-490.		1
356	Islet inflammation and ductal proliferation may be linked to increased pancreatitis risk in type 2 diabetes. <i>JCI Insight</i> , 2017, 2, .	5.0	17
357	Acute pancreatitis during GLP-1 receptor agonist treatment. A case report. <i>Medicine and Pharmacy Reports</i> , 2018, 91, 117-119.	0.4	9
358	Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions. <i>Annals of Translational Medicine</i> , 2018, 6, 131-131.	1.7	18
359	Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. <i>Current Pharmaceutical Design</i> , 2020, 26, 5911-5932.	1.9	8
360	Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence. <i>Current Diabetes Reviews</i> , 2020, 16, 699-715.	1.3	8
361	Isolation of Natural Compounds from <i>Syzygium densiflorum</i> Fruits and Exploring its Chemical Property, Therapeutic Role in Diabetic Management. <i>Natural Products Journal</i> , 2020, 10, 168-176.	0.3	2
362	Review of Associations Between Type 2 Diabetes and Cancer. <i>Clinical Diabetes</i> , 2020, 38, 256-265.	2.2	11
363	Drug induced acute pancreatitis: Does it exist?. <i>World Journal of Gastroenterology</i> , 2014, 20, 16529.	3.3	56
364	Newer oral and noninsulin therapies to treat type 2 diabetes mellitus. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, S18-S26.	1.3	5
365	Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 838.	0.4	6
366	Teneligliptin: Heraldng Change in Type 2 Diabetes. <i>Journal of Diabetes Mellitus</i> , 2016, 06, 113-131.	0.3	13
367	Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?. <i>Open Journal of Endocrine and Metabolic Diseases</i> , 2016, 06, 43-57.	0.2	1

#	ARTICLE	IF	CITATIONS
368	Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. <i>World Journal of Diabetes</i> , 2019, 10, 291-303.	3.5	14
369	Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model. <i>PeerJ</i> , 2016, 4, e1753.	2.0	6
370	Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2021, 14, 117955142110516.	1.9	6
371	Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. <i>Seminars in Nephrology</i> , 2021, 41, 331-348.	1.6	3
372	Antidiabetika. , 2014, , 393-418.		1
374	Initiation and intensification of antihyperglycemic therapy in type 2 diabetes mellitus: Update of Russian Association of Endocrinologists expert consensus document (2015). <i>Diabetes Mellitus</i> , 2015, 18, 5-23.	1.9	13
375	Antidiabetika. , 2016, , 301-318.		0
376	Antidiabetika. , 2018, , 353-368.		0
377	Adverse Drug Effects Involving the Gastrointestinal System (Pharmacist Perspective). , 2020, , 1-44.		0
378	Immunohistochemical Pharmacokinetics of the Anti-diabetes Drug Alogliptin in Rat Kidney and Liver. <i>Acta Histochemica Et Cytochemica</i> , 2020, 53, 55-60.	1.6	2
379	Application prospects of glucagon-like peptide-1 receptor agonists in treatment of metabolic diseases. <i>World Chinese Journal of Digestology</i> , 2020, 28, 393-400.	0.1	0
380	Avoiding Time-Related Biases: A Feasibility Study on Antidiabetic Drugs and Pancreatic Cancer Applying the Parametric g-Formula to a Large German Healthcare Database. <i>Clinical Epidemiology</i> , 2021, Volume 13, 1027-1038.	3.0	3
382	Overview of Type 2 Diabetes Drugs on the Market. <i>Journal of Biosciences and Medicines</i> , 2020, 08, 1-14.	0.2	2
383	Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 785-801.	4.7	0
384	Antidiabetika. , 2020, , 339-358.		0
385	Oral GLP1 Analog: Where Does the Tide Go?. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2020, 13, 117955142098413.	1.9	6
386	The Relationship Between Dipeptidyl Peptidase-4 Inhibitor Usage and Asymptomatic Amylase Lipase Increment in Type 2 Diabetes Mellitus Patients. <i>Turkish Journal of Pharmaceutical Sciences</i> , 2020, 17, 68-73.	1.4	3
387	Mildly symptomatic liraglutide-induced acute pancreatitis in a patient with type 2 diabetes mellitus: a case report. <i>The Egyptian Journal of Internal Medicine</i> , 2020, 32, .	0.9	2

#	ARTICLE	IF	CITATIONS
388	Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus. <i>GMS German Medical Science</i> , 2014, 12, Doc14.	2.7	2
389	Glucagonlike peptide 1 analogs in diabetes care. <i>Canadian Family Physician</i> , 2017, 63, 371.	0.4	0
391	Antidiabetika. , 2021, , 241-260.		0
392	Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?. <i>Journal of Internal Medicine</i> , 2022, 291, 557-573.	6.0	7
393	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: <i>Standards of Medical Care in Diabetesâ€™2022</i>. <i>Diabetes Care</i> , 2022, 45, S46-S59.	8.6	99
394	Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons. <i>Current Issues in Molecular Biology</i> , 2022, 44, 867-888.	2.4	2
395	Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management. <i>Hepatology Communications</i> , 2022, 6, 1250-1261.	4.3	3
396	Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin. <i>Journal of Translational Medicine</i> , 2021, 19, 520.	4.4	15
398	The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study. <i>Advances in Therapy</i> , 2022, 39, 2873-2888.	2.9	2
400	Pancreatic safety of DPP-4 inhibitors in type 2 diabetes mellitus. <i>Medicine (United States)</i> , 2022, 101, e29154.	1.0	1
401	Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary. <i>Clinical Diabetes</i> , 0, , .	2.2	1
404	Incretin based therapy and pancreatic cancer: Realising the reality. <i>World Journal of Gastroenterology</i> , 2022, 28, 2881-2889.	3.3	2
405	The spectrum of diabetes in acute and chronic pancreatitis. <i>Current Opinion in Gastroenterology</i> , 0, Publish Ahead of Print, .	2.3	2
406	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€™2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	2.1	146
407	Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. <i>Cardiovascular Research</i> , 2023, 119, 886-904.	3.8	6
409	Glucagon-like peptide-1 analogues for overweight or obese adults. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	0
410	Tirzepatide: A New Generation Therapeutic for Diabetes Type 2. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, .	1.2	1
411	Association of dipeptidyl peptidase-4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan. <i>Journal of Diabetes Investigation</i> , 0, , .	2.4	2

#	ARTICLE	IF	CITATIONS
412	Pharmacotherapy of type 2 diabetes: An update and future directions. <i>Metabolism: Clinical and Experimental</i> , 2022, 137, 155332.	3.4	35
413	Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-9.	2.5	9
414	The GLP-1 receptor agonists: whatâ€™s all the (cardiovascular) hype about?. <i>South African General Practitioner</i> , 2022, 3, 118-120.	0.1	0
415	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetesâ€™2023 </i>. <i>Diabetes Care</i> , 2023, 46, s49-s67.2.	8.6	58
416	GLP-1R Signaling and Functional Molecules in Incretin Therapy. <i>Molecules</i> , 2023, 28, 751.	3.8	7
417	Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. <i>Cancers</i> , 2023, 15, 485.	3.7	69
418	Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 4449-4461.	4.3	8
420	Weight Loss With Rising Blood Glucose: Challenges in Distinguishing Conventional Type 2 Diabetes From Pancreatic Cancerâ€™Associated Hyperglycemia. <i>Clinical Diabetes</i> , 0, , .	2.2	0
421	Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 407-418.	1.8	2
422	Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis. <i>International Journal of Clinical Pharmacy</i> , 2023, 45, 689-697.	2.1	1
423	Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. , 2023, , 365-396.		0
424	DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	10
425	Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. <i>Minerva Endocrinology</i> , 2023, 48, .	1.1	2
427	Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management. <i>Drugs</i> , 2023, 83, 1077-1090.	10.9	4
428	Medical Weight Optimization for Arthroplasty Patients: A Primer of Emerging Therapies for the Joint Arthroplasty Surgeon. <i>Journal of Arthroplasty</i> , 2024, 39, 38-43.	3.1	1
429	Advances in the management of type 2 diabetes in adults. , 2023, 2, e000372.		1
430	Linagliptin-Induced Pancreatitis. , 2023, 2, .		0
431	SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS. <i>Trakia Journal of Sciences</i> , 2023, 21, 54-62.	0.1	0

#	ARTICLE	IF	CITATIONS
432	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes. <i>Diabetes Care</i> , 2024, 47, S52-S76.	8.6	1
433	The role of hormones in ILC2-driven allergic airway inflammation. <i>Scandinavian Journal of Immunology</i> , 2024, 99, .	2.7	0
436	Overview of Inpatient Management of Hypertriglyceridemia Associated Acute Pancreatitis in Patients with Diabetes Mellitus. <i>Contemporary Endocrinology</i> , 2023, , 193-206.	0.1	0
437	Glucagon-like Peptide 1 Receptor Agonists and Cardiovascular Outcomes in Solid Organ Transplant Recipients With Diabetes Mellitus. <i>Transplantation</i> , 0, , .	1.0	0
438	GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment. <i>Gastroenterology Insights</i> , 2024, 15, 191-212.	1.2	0
440	Investigating incretins: a review of the use of GLP-1 and GIP receptor agonists for weight loss. <i>Journal of Aesthetic Nursing</i> , 2024, 13, 6-12.	0.1	0
441	Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. <i>Obesity Reviews</i> , 2024, 25, .	6.5	0